Argenica Therapeutics Limited (ASX:AGN)
Australia
· Delayed Price · Currency is AUD 0.6800
-0.0300 (-4.23%)
Jul 8, 2025, 3:55 PM AEST
Argenica Therapeutics Company Description
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia.
Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury.
Argenica Therapeutics Limited was incorporated in 2019 and is headquartered in Nedlands, Australia.
Argenica Therapeutics Limited
| Country | Australia |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Liz Dallimore |
Contact Details
Address: 117 Broadway Nedlands, 6009 Australia | |
| Phone | 61 8 9329 3396 |
| Website | argenica.com.au |
Stock Details
| Ticker Symbol | AGN |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000150328 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Liz Dallimore B.Sc., M.B.A., Ph.D. | Chief Executive Officer, MD and Director |
| Emma Waldon | Chief Financial Officer and Company Secretary |
| Prof. Bruno Philip Meloni | Chief Scientific Officer |